TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04816994
Drug: Single-dose of cannabis oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of cannabis oil in order to treat acute radicular pain
Study: NCT01001559
Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI)
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
Study: NCT02617680
Drug: desflurane - oxygen in nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
Study: NCT02475629
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
Study: NCT01878799
Drug: GS-7977/GS- 5885 FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
Study: NCT02025348
Drug: IntelliCap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
Study: NCT01520220
Drug: LY2784544
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
Study: NCT02757391
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04320706
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo orally
Study: NCT00901823
Drug: Diazoxide choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
Study: NCT00901823
Drug: Diazoxide choline high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
Study: NCT03219515
Drug: Gongjin-Dan
Normalized name: PANAX GINSENG FRUIT 229 mg in 4 g ORAL PELLET [Korea Gongjin-Dan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
Study: NCT03219515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
Study: NCT02242760
Drug: SB204 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically twice daily
Study: NCT02242760
Drug: SB204 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically daily
Study: NCT00386334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet one per day in the evening.
Study: NCT02337062
Drug: APD421
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337062
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03580005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Match Quillichew ERCT
Study: NCT02242760
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically twice and once daily
Study: NCT03341689
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: microcrystalline cellulose capsule
Study: NCT00391131
Drug: IgNextGen 16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
Study: NCT01233102
Drug: Conserved Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conserved Therapy
Study: NCT02781064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Study: NCT01318811
Drug: Dilute unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
Study: NCT01318811
Drug: Standard concentration unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
Study: NCT00398645
Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02059785
Drug: Pinocembrin for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04002401
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT03756129
Drug: MIJ821
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different dosages and different regimen for MIJ821
Study: NCT03756129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT02461329
Drug: Gelofusine® B. Braun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
Study: NCT01978457
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03211065
Drug: 20% subcutaneous immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Immunoglobulin
Study: NCT02461329
Drug: Ringerfundin ® B. Braun
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
Study: NCT02337751
Drug: TVP-1012 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVP-1012 1mg Tablets
Study: NCT03373201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00218660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02321852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral administration of placebo mannitol for 7 days
Study: NCT02442492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Study: NCT02947893
Drug: Placebo Capsule(s) Once a Day by Mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
Study: NCT01107730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01524601
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg rosuvastatin for 4 weeks
Study: NCT04159896
Drug: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00813111
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg SKY0402 instilled into breast pocket during surgery
Study: NCT02238353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01293305
Drug: Chondroitin sulfate + Glucosamine sulfate
Normalized name: chondroitin sulfates / glucosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.
Study: NCT02735031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks treatment with placebo on top of insulin treatment
Study: NCT01568853
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously, 10 ug/min, 24 hours
Study: NCT04905043
Drug: SmartPill®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
Study: NCT00915590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custom eye drop eye three times a day in both eyes for a period of 6 weeks
Study: NCT03356860
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV Q 2 weeks from week 14 to week 20
Study: NCT00681460
Drug: human recombined insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
Study: NCT01934361
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
Study: NCT02440009
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
Study: NCT02962960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration every two weeks from week 0 to week 50
Study: NCT00638781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00179140
Drug: nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
Study: NCT02426697
Drug: fentanyl transmucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Study: NCT02426697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Study: NCT04395768
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Study: NCT04159961
Drug: DWJ211
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject the Drug into submental fat and abdominal fat via subcutaneous
Study: NCT03293641
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
Study: NCT00494663
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg tablet once per day for 16 weeks
Study: NCT00494663
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg tablet once per day for 16 weeks
Study: NCT00494663
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg DIO-902 tablet once daily for 16 weeks
Study: NCT00494663
Drug: DIO-902 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DIO-902 placebo tablet once daily for 16 weeks
Study: NCT00494663
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg tablet of DIO-902 once daily for 16 weeks
Study: NCT00494663
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg DIO-902 tablet daily for 16 weeks
Study: NCT00494663
Drug: DIO-902
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450mg DIO-902 tablet for 16 weeks
Study: NCT00578903
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
Study: NCT04974073
Drug: PHY606
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
Study: NCT00003012
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003012
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003012
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003012
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02858401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once every 2 weeks
Study: NCT02858401
Drug: ARV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
Study: NCT00689065
Drug: CALAA-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
Study: NCT04556760
Drug: AZD9567
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
Study: NCT04556760
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
Study: NCT04536363
Drug: Analogs, Prostaglandin E1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days
Study: NCT02202005
Drug: Viramune®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viramune® 400 mg Retardtabletten
Study: NCT02947269
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT05468892
Drug: Trifluridine Tipiracil
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest
Study: NCT00107822
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01818583
Drug: Glucose 50 MG/ML
Normalized name: glucose 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04536363
Drug: Standard therapeutic protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours
Study: NCT01780181
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
Study: NCT01780181
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
Study: NCT01642251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of Veliparib
Study: NCT01614912
Drug: SM-13496
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 or 80 mg once daily orally
Study: NCT01792739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)
Study: NCT02073747
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour inhaled normal saline
Study: NCT02168920
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 10 weeks
Study: NCT02762032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo supplement to take BID for 14 weeks in Arm 3
Study: NCT03064113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03064113
Drug: TD-4208 350 μg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02168920
Drug: 3 mg/day
Normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 10 weeks
Study: NCT02168920
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 10 weeks
Study: NCT02168920
Drug: Placebo (0 mg/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 10 weeks
Study: NCT01620476
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Study: NCT01202760
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01202760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00129675
Drug: [123I]ß CIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Study: NCT00110123
Drug: isolated perfusion
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00541957
Drug: Medication prescribed by PCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Can include any antidepressant medication
Study: NCT02669173
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
Study: NCT03702777
Drug: ASP8302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT03702777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule